Ghent University Academic Bibliography

Advanced

Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club

JJ Body, P Bergmann, S Boonen, Y Boutsen, JP Devogelaer, Stefan Goemaere, Jean Kaufman UGent, S Rozenberg and JY Reginster (2010) OSTEOPOROSIS INTERNATIONAL. 21(10). p.1657-1680
abstract
Several drugs are available for the management of postmenopausal osteoporosis. This may, in daily practice, confuse the clinician. This manuscript offers an evidence-based update of previous treatment guidelines, with a critical assessment of the currently available efficacy data on all new chemical entities which were granted a marketing authorization. Osteoporosis is widely recognized as a major public health concern. The availability of new therapeutic agents makes clinical decision-making in osteoporosis more complex. Nation-specific guidelines are needed to take into consideration the specificities of each and every health care environment. The present manuscript is the result of a National Consensus, based on a systematic review and a critical appraisal of the currently available literature. It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect.
Please use this url to cite or link to this publication:
author
organization
year
type
journalArticle (original)
publication status
published
subject
keyword
RANDOMIZED CONTROLLED-TRIAL, VITAMIN-D SUPPLEMENTATION, MONTHLY ORAL IBANDRONATE, VERTEBRAL FRACTURE RISK, CONTINUING OUTCOMES RELEVANT, HORMONE REPLACEMENT THERAPY, INTRAVENOUS ZOLEDRONIC ACID, CONTROLLED CLINICAL-TRIAL, PLACEBO-CONTROLLED TRIAL, LONG-TERM EXTENSION, Bisphosphonate, Osteoporosis, Raloxifene, Strontium, Teriparatide
journal title
OSTEOPOROSIS INTERNATIONAL
Osteoporosis Int.
volume
21
issue
10
pages
1657 - 1680
Web of Science type
Article
Web of Science id
000281543200003
JCR category
ENDOCRINOLOGY & METABOLISM
JCR impact factor
4.859 (2010)
JCR rank
23/115 (2010)
JCR quartile
1 (2010)
ISSN
0937-941X
DOI
10.1007/s00198-010-1223-4
language
English
UGent publication?
yes
classification
A1
copyright statement
I have transferred the copyright for this publication to the publisher
id
1194299
handle
http://hdl.handle.net/1854/LU-1194299
date created
2011-03-22 14:27:12
date last changed
2016-12-19 15:45:14
@article{1194299,
  abstract     = {Several drugs are available for the management of postmenopausal osteoporosis. This may, in daily practice, confuse the clinician. This manuscript offers an evidence-based update of previous treatment guidelines, with a critical assessment of the currently available efficacy data on all new chemical entities which were granted a marketing authorization. Osteoporosis is widely recognized as a major public health concern. The availability of new therapeutic agents makes clinical decision-making in osteoporosis more complex. Nation-specific guidelines are needed to take into consideration the specificities of each and every health care environment. The present manuscript is the result of a National Consensus, based on a systematic review and a critical appraisal of the currently available literature. It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect.},
  author       = {Body, JJ and Bergmann, P and Boonen, S and Boutsen, Y and Devogelaer, JP and Goemaere, Stefan and Kaufman, Jean and Rozenberg, S and Reginster, JY},
  issn         = {0937-941X},
  journal      = {OSTEOPOROSIS INTERNATIONAL},
  keyword      = {RANDOMIZED CONTROLLED-TRIAL,VITAMIN-D SUPPLEMENTATION,MONTHLY ORAL IBANDRONATE,VERTEBRAL FRACTURE RISK,CONTINUING OUTCOMES RELEVANT,HORMONE REPLACEMENT THERAPY,INTRAVENOUS ZOLEDRONIC ACID,CONTROLLED CLINICAL-TRIAL,PLACEBO-CONTROLLED TRIAL,LONG-TERM EXTENSION,Bisphosphonate,Osteoporosis,Raloxifene,Strontium,Teriparatide},
  language     = {eng},
  number       = {10},
  pages        = {1657--1680},
  title        = {Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club},
  url          = {http://dx.doi.org/10.1007/s00198-010-1223-4},
  volume       = {21},
  year         = {2010},
}

Chicago
Body, JJ, P Bergmann, S Boonen, Y Boutsen, JP Devogelaer, Stefan Goemaere, Jean Kaufman, S Rozenberg, and JY Reginster. 2010. “Evidence-based Guidelines for the Pharmacological Treatment of Postmenopausal Osteoporosis: a Consensus Document by the Belgian Bone Club.” Osteoporosis International 21 (10): 1657–1680.
APA
Body, J., Bergmann, P., Boonen, S., Boutsen, Y., Devogelaer, J., Goemaere, S., Kaufman, J., et al. (2010). Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. OSTEOPOROSIS INTERNATIONAL, 21(10), 1657–1680.
Vancouver
1.
Body J, Bergmann P, Boonen S, Boutsen Y, Devogelaer J, Goemaere S, et al. Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. OSTEOPOROSIS INTERNATIONAL. 2010;21(10):1657–80.
MLA
Body, JJ, P Bergmann, S Boonen, et al. “Evidence-based Guidelines for the Pharmacological Treatment of Postmenopausal Osteoporosis: a Consensus Document by the Belgian Bone Club.” OSTEOPOROSIS INTERNATIONAL 21.10 (2010): 1657–1680. Print.